CY1110915T1 - Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων - Google Patents
Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονωνInfo
- Publication number
- CY1110915T1 CY1110915T1 CY20101101030T CY101101030T CY1110915T1 CY 1110915 T1 CY1110915 T1 CY 1110915T1 CY 20101101030 T CY20101101030 T CY 20101101030T CY 101101030 T CY101101030 T CY 101101030T CY 1110915 T1 CY1110915 T1 CY 1110915T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pml
- gene codes
- androgen receptors
- specific suppression
- complementary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
Abstract
Η εφεύρεση αφορά ένα διπλόκλωνο ολιγονουκλεοτίδιο που χαρακτηρίζεται από το ότι συνίσταται από δύο συμπληρωματικές ολιγονουκλεοτιδικές αλληλουχίες που σχηματίζουν ένα υβρίδιο που περιλαμβάνει κάθε μία από αυτές σε ένα από τα 3' ή 5' άκρα αυτής ένα έως πέντε μη-ζευγαρωμένα νουκλεοτίδια που σχηματίζουν μονόκλωνα άκρα αλληλοκαλυπτόμενα από το υβρίδιο, μία δε των εν λόγω ολιγονουκλεοτιδικών αλληλουχιών ουσιαστικά είναι συμπληρωματική μιας αλληλουχίας στόχου που ανήκει σε ένα DNA ή RNA μόριο που θα καταστέλλετε ειδικά. Η εφεύρεση επίσης αφορά την χρήση των εν λόγω ολιγονουκλεοτιδίων στις φαρμακευτικές συνθέσεις κυρίως για την θεραπευτική αγωγή καρκίνων.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0114549A FR2832154B1 (fr) | 2001-11-09 | 2001-11-09 | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
FR0204474A FR2838442B1 (fr) | 2001-11-09 | 2002-04-10 | Sirnas inhibiteurs de l'expression de genes responsables de l'inactivation de la p53 et leur utilisation dans le traitement des cancers |
EP02793219A EP1453962B1 (fr) | 2001-11-09 | 2002-11-08 | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un recepteur aux androgenes |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110915T1 true CY1110915T1 (el) | 2015-06-10 |
Family
ID=26213261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101101030T CY1110915T1 (el) | 2001-11-09 | 2010-11-17 | Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων |
Country Status (12)
Country | Link |
---|---|
US (2) | US7371735B2 (el) |
EP (3) | EP3037537A1 (el) |
JP (1) | JP4323952B2 (el) |
AT (1) | ATE478143T1 (el) |
AU (1) | AU2002358881A1 (el) |
CA (2) | CA2466773C (el) |
CY (1) | CY1110915T1 (el) |
DE (1) | DE60237391D1 (el) |
DK (1) | DK1453962T3 (el) |
FR (2) | FR2832154B1 (el) |
PT (1) | PT1453962E (el) |
WO (1) | WO2003040366A2 (el) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
DE10100586C1 (de) * | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
EP1438405A1 (de) * | 2001-01-09 | 2004-07-21 | Ribopharma AG | Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens |
WO2003035869A1 (de) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens |
DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
EP1445312B1 (en) * | 2001-11-21 | 2012-12-26 | Astellas Pharma Inc. | Method of inhibiting gene expression |
AU2003242688A1 (en) * | 2002-06-20 | 2004-01-06 | Dsm Ip Assets B.V. | Inhibition of nuclear receptors |
US8090542B2 (en) * | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
US7781575B2 (en) * | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
GB0306148D0 (en) * | 2003-03-18 | 2003-04-23 | Milner Jo | Regulation of gene expression |
EP1735009A4 (en) * | 2004-03-12 | 2011-03-30 | Alnylam Pharmaceuticals Inc | RNAI AGENTS TARGETING THE VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF) |
CN101277704A (zh) | 2005-04-12 | 2008-10-01 | 因特拉迪格姆公司 | 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法 |
US7893244B2 (en) | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
WO2007011819A2 (en) * | 2005-07-15 | 2007-01-25 | The Penn State Research Foundation | Ferritin as a therapeutic target in abnormal cells |
US20100286229A1 (en) * | 2005-09-30 | 2010-11-11 | Katerina Gurova | Modulation of Androgen Receptor for Treatment of Prostate Cancer |
CA2629564C (en) * | 2005-11-15 | 2014-04-22 | Genoid Kft. | Method of detecting pathogens |
US7740880B2 (en) * | 2006-03-03 | 2010-06-22 | University Of Utah Research Foundation | Polymeric carrier for delivery of small interfering RNA |
HUE037173T2 (hu) | 2006-08-08 | 2018-08-28 | Univ Bonn Rheinische Friedrich Wilhelms | 5'-Foszfát-oligonukleotidok szerkezete és alkalmazása |
AR055648A1 (es) * | 2006-09-21 | 2007-08-29 | Gen Med Sa | Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos |
WO2009031671A1 (ja) * | 2007-09-07 | 2009-03-12 | The University Of Tokushima | p53の発現促進方法およびそれに用いるp53発現促進剤 |
DE102008014318B4 (de) * | 2008-03-14 | 2021-02-04 | Premark Feg L.L.C. | Transportspülmaschine und Verfahren zum Betreiben einer Transportspülmaschine |
JP5689413B2 (ja) | 2008-05-21 | 2015-03-25 | ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン | 平滑末端を有する5’三リン酸オリゴヌクレオチドおよびその使用 |
CA2762524A1 (en) * | 2009-05-18 | 2011-01-13 | Ensysce Biosciences, Inc. | Carbon nanotubes complexed with multiple bioactive agents and methods related thereto |
AU2011282902B2 (en) | 2010-07-28 | 2015-01-29 | Alcon Research, Ltd. | siRNA targeting VEGFA and methods for treatment in vivo |
WO2012016139A2 (en) * | 2010-07-29 | 2012-02-02 | Sirnaomics, Inc. | Sirna compositions and methods for treatment of hpv and other infections |
EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
AU2012353330B2 (en) | 2011-12-16 | 2018-04-19 | National University Corporation Tokyo Medical And Dental University | Chimeric double-stranded nucleic acid |
EP2867368B1 (en) | 2012-07-06 | 2022-01-12 | Institut Gustave Roussy | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer |
US9868952B2 (en) | 2012-07-08 | 2018-01-16 | Sirnaomics, Inc. | Compositions and methods for “resistance-proof” SiRNA therapeutics for influenza |
EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
AR092982A1 (es) | 2012-10-11 | 2015-05-13 | Isis Pharmaceuticals Inc | Modulacion de la expresion de receptores androgenicos |
MA40782A (fr) * | 2014-10-03 | 2017-08-08 | Hocuslocus Llc | Procédés et compositions utilisant un arn non codant en vue de la culture et de la sélection de cellules |
CA3041630A1 (fr) * | 2016-10-27 | 2018-05-03 | Selexel | Nouvel oligonucleotide double brin bisquecifiques pour le traitement des cancers |
EP3755802A4 (en) * | 2018-02-21 | 2021-11-17 | Singapore Health Services Pte Ltd | CANCER THERAPEUTIC TARGETING USING MUTED P53-SPECIFIC SIRNA |
EP3946629A4 (en) * | 2019-03-26 | 2023-04-05 | University Of Massachusetts | THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4714613A (en) * | 1982-09-30 | 1987-12-22 | The Albert Einstein College Of Medicine Of Yeshiva University | Method of suppressing cell growth by immunotherapy |
US5165923A (en) * | 1989-11-20 | 1992-11-24 | Imperial Cancer Research Technology | Methods and compositions for the treatment of hodgkin's disease |
JPH08506961A (ja) * | 1993-02-19 | 1996-07-30 | ジンタ・インコーポレイテッド | アンチセンスオリゴマー類を使用するアンドロゲン関連禿頭症の治療 |
US5641756A (en) * | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
AU7983294A (en) | 1993-10-19 | 1995-05-08 | Regents Of The University Of Michigan, The | P53-mediated apoptosis |
US5556956A (en) * | 1993-11-04 | 1996-09-17 | Board Of Regents, The University Of Texas System | Methods and compositions relating to the androgen receptor gene and uses thereof |
US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
US6150092A (en) * | 1994-06-27 | 2000-11-21 | Taogosei Company, Ltd. | Antisense nucleic acid compound targeted to VEGF |
WO1996018733A2 (en) * | 1994-12-14 | 1996-06-20 | Innovir Laboratories, Inc. | Ribozyme-mediated inactivation of leukemia-associated rna |
US5882914A (en) | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
US6426335B1 (en) * | 1997-10-17 | 2002-07-30 | Gilead Sciences, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
CN1295617A (zh) * | 1998-02-06 | 2001-05-16 | 科莱特诺医疗公司 | 血管生成因子-血管内皮细胞生长因子vegf的突变体 |
EP0978561A1 (en) | 1998-08-07 | 2000-02-09 | Hoechst Marion Roussel Deutschland GmbH | Antisense oligonucleotides for the inhibition of VEGF expression |
US6214986B1 (en) * | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
DE69932346T2 (de) | 1998-10-26 | 2007-07-05 | Avi Biopharma, Inc., Portland | Auf Morpholin basierendes p53-Antisense- Oligonucleotid und dessen Verwendungen |
IL145778A0 (en) * | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
GB9910119D0 (en) | 1999-04-30 | 1999-06-30 | Novartis Ag | Organic compounds |
AU5717400A (en) | 1999-06-14 | 2001-01-02 | Cancer Research Ventures Limited | Cancer therapy |
GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
AU2925401A (en) | 2000-01-19 | 2001-07-31 | Parkash S Gill | Methods and compositions for antisense vegf oligonucleotides |
WO2001075164A2 (en) * | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
WO2003070910A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
CA2448320A1 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Ribozyme based treatment of female reproductive diseases |
US20040235171A1 (en) | 2001-07-17 | 2004-11-25 | Milner Ann Josephine | Silencing of gene expression by sirna |
EP1442143A4 (en) | 2002-02-20 | 2005-02-16 | Sirna Therapeutics Inc | INHIBITION OF RNA INTERFERENCE-INDUCED BCL2 GENE EXPRESSION USING SMALL INTERFERING NUCLEIC ACIDS (SINA) |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
CA2501065A1 (en) | 2002-09-04 | 2004-03-18 | Johnson & Johnson Research Pty Ltd | Methods using dsdna to mediate rna interference (rnai) |
AU2003291678B2 (en) | 2002-11-01 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of HIF-1 alpha |
EP1735009A4 (en) | 2004-03-12 | 2011-03-30 | Alnylam Pharmaceuticals Inc | RNAI AGENTS TARGETING THE VASCULAR ENDOTHELIUM GROWTH FACTOR (VEGF) |
EP2712926A2 (en) * | 2008-03-05 | 2014-04-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 and VEGF genes |
WO2010105209A1 (en) * | 2009-03-12 | 2010-09-16 | Alnylam Pharmaceuticals, Inc. | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
WO2011017548A1 (en) | 2009-08-05 | 2011-02-10 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
CN107519133A (zh) | 2009-09-15 | 2017-12-29 | 阿尔尼拉姆医药品有限公司 | 脂质配制的组合物及抑制Eg5和VEGF基因的表达的方法 |
-
2001
- 2001-11-09 FR FR0114549A patent/FR2832154B1/fr not_active Expired - Lifetime
-
2002
- 2002-04-10 FR FR0204474A patent/FR2838442B1/fr not_active Expired - Fee Related
- 2002-11-08 DE DE60237391T patent/DE60237391D1/de not_active Expired - Lifetime
- 2002-11-08 DK DK02793219.3T patent/DK1453962T3/da active
- 2002-11-08 AU AU2002358881A patent/AU2002358881A1/en not_active Abandoned
- 2002-11-08 US US10/494,800 patent/US7371735B2/en not_active Expired - Lifetime
- 2002-11-08 EP EP16153703.0A patent/EP3037537A1/fr not_active Withdrawn
- 2002-11-08 AT AT02793219T patent/ATE478143T1/de active
- 2002-11-08 EP EP02793219A patent/EP1453962B1/fr not_active Expired - Lifetime
- 2002-11-08 WO PCT/FR2002/003843 patent/WO2003040366A2/fr active Application Filing
- 2002-11-08 PT PT02793219T patent/PT1453962E/pt unknown
- 2002-11-08 CA CA2466773A patent/CA2466773C/fr not_active Expired - Lifetime
- 2002-11-08 CA CA2789407A patent/CA2789407C/fr not_active Expired - Lifetime
- 2002-11-08 EP EP08001984.7A patent/EP1939291B1/fr not_active Expired - Lifetime
- 2002-11-08 JP JP2003542613A patent/JP4323952B2/ja not_active Expired - Fee Related
-
2008
- 2008-02-28 US US12/072,803 patent/US8318689B2/en not_active Expired - Lifetime
-
2010
- 2010-11-17 CY CY20101101030T patent/CY1110915T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
FR2832154B1 (fr) | 2007-03-16 |
FR2838442B1 (fr) | 2007-06-08 |
EP1453962A2 (fr) | 2004-09-08 |
EP1453962B1 (fr) | 2010-08-18 |
PT1453962E (pt) | 2010-11-29 |
WO2003040366A3 (fr) | 2004-07-01 |
FR2838442A1 (fr) | 2003-10-17 |
CA2466773A1 (fr) | 2003-05-15 |
JP4323952B2 (ja) | 2009-09-02 |
US20080287385A1 (en) | 2008-11-20 |
DE60237391D1 (de) | 2010-09-30 |
US7371735B2 (en) | 2008-05-13 |
US8318689B2 (en) | 2012-11-27 |
EP1939291A3 (fr) | 2012-02-22 |
EP1939291A2 (fr) | 2008-07-02 |
EP3037537A1 (fr) | 2016-06-29 |
WO2003040366A2 (fr) | 2003-05-15 |
JP2005508188A (ja) | 2005-03-31 |
CA2466773C (fr) | 2012-10-16 |
CA2789407A1 (fr) | 2003-05-15 |
DK1453962T3 (da) | 2010-12-20 |
AU2002358881A1 (en) | 2003-05-19 |
CA2789407C (fr) | 2017-10-31 |
ATE478143T1 (de) | 2010-09-15 |
US20050215497A1 (en) | 2005-09-29 |
FR2832154A1 (fr) | 2003-05-16 |
EP1939291B1 (fr) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110915T1 (el) | Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων | |
Arzumanov et al. | Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2 ‘-O-methyl/LNA oligoribonucleotides | |
AU660679B2 (en) | Closed sense and antisense oligonucleotides and uses thereof | |
Fabani et al. | miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA–peptide conjugates | |
US5989912A (en) | Three component chimeric antisense oligonucleotides | |
US5849902A (en) | Three component chimeric antisense oligonucleotides | |
ZA200304500B (en) | Method for inhibiting the expression of a target gene and medicament for treating a tumor disease. | |
IL166546A (en) | Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene | |
JP2015523853A5 (el) | ||
CA2385853A1 (en) | Design of high affinity rnase h recruiting oligonucleotide | |
JP2002510207A (ja) | 拡張された開裂ルールを有するハンマーヘッドリボザイム | |
RU2010120715A (ru) | Модифицированная липидом двухцепочечная рнк, обладающая сильным эффектом рнк-интерференции | |
FR2790757B1 (fr) | Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant. | |
AU5720098A (en) | G-rich oligo aptamers and methods of modulating an immune response | |
Arzumanov et al. | Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction | |
Holmes et al. | Steric inhibition of human immunodeficiency virus type‐1 Tat‐dependent trans‐activation in vitro and in cells by oligonucleotides containing 2′‐O‐methyl G‐clamp ribonucleoside analogues | |
JP2007530431A5 (el) | ||
CA3216819A1 (en) | Gene expression regulatory system using crispr system | |
Williamson | G-quartets in biology: reprise. | |
JP6882735B2 (ja) | 構造強化されたmiRNA阻害剤S−TuD | |
Abe et al. | Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligonucleotides | |
DE60110244D1 (de) | Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose-nukleotide | |
JP2009504190A5 (el) | ||
Yamakawa et al. | Properties of nicked and circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligodeoxynucleotides | |
AU2001258274A1 (en) | Synthetic oligonucleotides as inducers of erythroid differentiation |